# Animol Discovery

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/animol-discovery

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.animol-discovery.com
- Total disclosed funding: $38M
- Latest round: Series B (Jul 15, 2022)
- Investors on record: 3

## About

Animol Discovery, Inc. is a biopharmaceutical company dedicated to developing novel pharmaceutical ingredients specifically for veterinary medicine, addressing critical healthcare needs for both companion and farm animals.Founded in 2019, Animol Discovery, Inc. is based in Boston, US, and specializes in the discovery and development of pharmaceutical products for veterinary use. The company has undergone no significant operational pivots and does not operate as a subsidiary. Brett Chevalier, the founder, has a history of entrepreneurship in the life sciences sector. As of July 2022, Animol successfully raised USD 32.00 mn in a Series B funding round led by Novalis LifeSciences, with participation from Anterra Capital and Finistere Ventures, bringing the total amount raised to USD 32.00 mn and valuing the company at USD 55.17 mn.Animol Discovery focuses on creating proprietary small molecules aimed at veterinary medicine, targeting therapeutic areas such as anti-parasitics and chronic disease treatments. Their innovative research utilizes advanced technologies, including genomics analysis and artificial intelligence, to enhance drug discovery processes. The company is committed to improving animal health outcomes through its carefully developed pharmaceuticals, which are intended for various geographical markets where animal healthcare is prioritized.Animol Discovery generates revenue through partnerships with veterinary pharmaceutical distributors and manufacturers, primarily engaging in business-to-business transactions. Revenue streams include successful commercialization of proprietary small molecules developed through its technology platform, with a focus on long-term client relationships fostered through licensing agreements and research collaborations.Following the Series B funding round in July 2022, Animol Discovery plans to utilize the raised USD 32.00 mn to focus on clinical drug trials aimed at enhancing its pharmaceutical product inventory. The company is also looking to introduce new products, although specific launch dates have not been disclosed. Additionally, Animol aims to expand into new markets, particularly in regions with growing veterinary healthcare needs, ensuring that their innovative offerings reach a wider audience.

## Funding rounds

- Series B, Jul 15, 2022, $32M — Finistere Ventures, Anterra Capital, Novalis LifeSciences
- Series A, Jan 1, 2020, $6M — Anterra Capital

## Investors

- Anterra Capital (https://capitalatlas.ai/funds/anterra-capital) — Series A, Series B
- Finistere Ventures (https://capitalatlas.ai/funds/finistere-ventures) — Series B
- Novalis LifeSciences (https://capitalatlas.ai/funds/novalis-lifesciences) — Series B